Crystalline Forms of Formula (I) Compounds for Cancer Treatment
Summary
The USPTO granted Patent US12606553B2 to Foghorn Therapeutics Inc., covering crystalline forms of a formula (I) compound and compositions containing those forms. The patent also protects methods of using the crystalline forms for treating cancer in subjects, including administration of an effective amount of the compound. The patent, classified under CPC C07D 417/14 (organic chemistry, heterocyclic compounds), contains 11 claims.
What changed
The USPTO issued Patent US12606553B2 to Foghorn Therapeutics Inc., granting exclusive rights to crystalline forms of a formula (I) compound and pharmaceutical compositions containing those forms. The patent also covers methods of treating cancer by administering an effective amount of the crystalline compound to a subject in need thereof. The patent contains 11 claims and was filed on March 9, 2022, with application number 18281022.
Pharmaceutical manufacturers and drug developers should be aware that Foghorn Therapeutics now holds exclusive rights to these specific crystalline forms and their therapeutic applications. Any entity seeking to develop competing cancer treatments using similar crystalline forms would need to design around this patent or seek a licensing arrangement with Foghorn. The patent's broad 'methods of treating cancer' claim language suggests potential enforcement risks for generic or biosimilar developers working in this chemical space.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Crystalline forms, compositions containing same, and methods of their use
Grant US12606553B2 Kind: B2 Apr 21, 2026
Assignee
FOGHORN THERAPEUTICS INC.
Inventors
Rishi G. Vaswani, Chong-Hui Gu
Abstract
Disclosed are crystalline forms of the compound of formula (I): (I) Also disclosed are compositions containing the crystalline forms of the compound of formula (I) and methods of their use. The methods may be for treating cancer in a subject in need thereof, e.g., by administering to the subject an effective amount of the crystalline form disclosed herein or its composition.
CPC Classifications
C07D 417/14
Filing Date
2022-03-09
Application No.
18281022
Claims
11
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.